Puma Biotechnology Initiates Phase II ALISCA®-Lung2 Trial of Alisertib Plus Paclitaxel in Advanced Small Cell Lung Cancer

Puma Biotechnology Initiates Phase II ALISCA®-Lung2 Trial of Alisertib and Paclitaxel in Advanced Small Cell Lung Cancer Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company focused on developing innovative cancer…

Read MorePuma Biotechnology Initiates Phase II ALISCA®-Lung2 Trial of Alisertib Plus Paclitaxel in Advanced Small Cell Lung Cancer